Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
University of Pittsburgh
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Dana-Farber Cancer Institute
Intensity Therapeutics, Inc.
Northwestern University
University of Washington
Bristol-Myers Squibb
Bristol-Myers Squibb
Incyte Corporation
Incyte Corporation